RUNX2 and prostate carcinoma: In prostate cancer, the increased expression of RUNX2 under nitric oxide conditions conferred resistance to docetaxel in LNCaP cells, and activation of the ERK-PI3K-AP1-RUNX2 axis was indicated [25].